

Publieksdag
Hersentumoren



Neuro-oncologie in cijfers

Vincent Ho

Epidemioloog / onderzoeker

Integraal Kankercentrum Nederland (IKNL)

Zaterdag 16 maart 2024
De Landgoederij, Bunnik



In samenwerking met:




Epidemiologie?



Hersentumoren zijn toch geen epidemieën?


Nee, maar:

- gebruik van (statistische) methoden
- bestudeert bepaalde factoren van ziekte
- gericht op populaties





- Databron
 - Nederlandse kankerregistratie (NKR)
 - Dutch Brain Tumour Registry (DBTR)
- Cijfers gliomen / meningeomen
 - Hoe vaak komen deze tumoren voor?
 - Hoe worden patiënten behandeld?
 - Hoe is de overleving van patiënten?



Nederlandse kankerregistratie (NKR)




WERELD
KANKER
DAG4FEB

128.000

nieuwe kankerdiagnoses in 2023


128.000 nieuwe kankerpatiënten in 2023 – meer diagnoses in vroeg stadium



Nieuwe publicatie onthult verband tussen inkomen en kankerdiagnoses



Nederlandse Kankeratlas toont impact van kanker per regio






Publieksdag
Hersentumoren




Nederlandse kankerregistratie (NKR)

- Landelijke dekking sinds 1989
 - regionaal soms vanaf 1955
- Bijna 130.000 nieuwe diagnoses per jaar
 - database: >2 miljoen cases
- Compleetheid geschat op 90–95%
- Registratie door datamanagers IKNL



Dutch Brain Tumour Registry (DBTR)

- Aanvullende registratie neuro-oncologie
 - gliomen: vanaf 2014
 - meningeomen: vanaf 2016
- Samenwerking
 - Landelijke Werkgroep Neuro-Oncologie (LWNO)
 - IKNL
- Doel (wetenschappelijk onderzoek en statistiek)
 - inzichtelijk en transparant maken van neuro-oncologische zorg
 - bijdragen aan kwaliteitsbewaking en -verbetering



Dataverzameling




pathologie-
laboratoria

klinische
diagnoses

andere databases


D
D
H
D
D

NKR /
DBTR



Neuro-oncologie in Nederland

AANTAL NIEUWE DIAGNOSES IN DE PERIODE 2000–2022





(borstkanker: >3 miljoen nieuwe diagnoses)





Gliomen

AANTAL DIAGNOSES GLIOMEN IN DE PERIODE 2000–2022



Gliomen


AANTAL DIAGNOSES GLIOMEN IN DE PERIODE 2000–2022



Gliomen

GLIOMEN IN DE PERIODE 2014–2022 PER TYPE

pathologisch bevestigde diagnoses




■ glioblastoom

■ oligodendroglioom graad 2-3



■ astrocytoom graad 2-4

■ overige gliomen



Gliomen



GLIOMEN IN DE PERIODE 2016–2022 LEEFTIJD PER TYPE



Gliomen



NEUROCHIRURGIE BIJ GLIOMEN IN DE PERIODE 2014–2022 PER TYPE

pathologisch bevestigde diagnoses





Gliomen

BEHANDELING BIJ GLIOMEN IN DE PERIODE 2014–2022 PER TYPE





Gliomen

OVERLEVING BIJ GLIOMEN IN DE PERIODE 2014–2022 PER GRAAD





Meningeomen

AANTAL DIAGNOSES MENINGEOMEN IN DE PERIODE 2000–2022



Meningeomen



AANTAL DIAGNOSES MENINGEOMEN IN DE PERIODE 2000–2022



Meningeomen



MENINGEOMEN IN DE PERIODE 2016–2022 PER GRAAD

pathologisch bevestigde diagnoses



Meningeomen



MENINGEOMEN IN DE PERIODE 2016–2022 LEEFTIJD PER GRAAD



Meningeomen

NEUROCHIRURGIE BIJ MENINGEOMEN IN DE PERIODE 2016–2022



pathologisch bevestigde diagnoses



Meningeomen



BEHANDELING BIJ MENINGEOMEN IN DE PERIODE 2016–2022

PER GRAAD




Meningeomen

OVERLEVING BIJ MENINGEOMEN IN DE PERIODE 2016–2022 PER GRAAD



Take home message

- Het aantal diagnoses van gliomen en meningeomen stijgt
 - gliomen: met name door veroudering van de bevolking
 - meningeomen: mede door betere registratie en detectie
- De overleving bij glioblastomen moet worden verbeterd
- Registraties zoals de DBTR
 - brengen ziektepatronen in kaart
 - geven inzicht in geleverde zorg
 - bieden mogelijkheden voor onderzoek met 'real life data'



Dank voor uw aandacht

